These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25145552)

  • 1. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
    Yacoub A; Odenike O; Verstovsek S
    Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
    Harrison CN; Talpaz M; Mead AJ
    Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental Therapeutics in Myeloproliferative Neoplasms.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical management of patients with myelofibrosis receiving ruxolitinib.
    Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
    Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.
    Mesa RA; Cortes J
    J Hematol Oncol; 2013 Oct; 6():79. PubMed ID: 24283870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
    Mascarenhas J; Mughal TI; Verstovsek S
    Curr Med Chem; 2012; 19(26):4399-413. PubMed ID: 22830345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
    Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
    J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.